2024-10-22 10:39:35
Brii Bio Announces Amubarvimab/Romlusevimab Combination Received Approval from NMPA as First COVID-19 Neutralizing Antibody Combination Therapy in China
Corporate/ 2023-07-23
Brii Bio Announces Amubarvimab/Romlusevi...

The approval marks the first locally-discovered and approved SARS-CoV-2 target-specific treatment in China,through a randomized,double-blind...

Servatus raises $7.5 million to advance autoimmune therapies with its microbial biotherapeutics clinical programs
Health/ 2023-07-22
Servatus raises $7.5 million to advance ...

Servatus has raised $7.5 million in an oversubscribed capital raise,with strong support from sophisticated shareholders

CUSMail

CusMail provide the Latest News , Business and Technology News Release service. Most of our news is paid for distribution to meet global marketing needs. We can provide you with global market support.

© CUSMAIL. All Rights Reserved. Operate by Paid Release